Literature DB >> 14615380

Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment.

Corey Casper1, W Garrett Nichols, Meei-Li Huang, Lawrence Corey, Anna Wald.   

Abstract

Multicentric Castleman disease (MCD) is a lymphoproliferative disorder associated with human herpesvirus 8 (HHV-8) infection among persons with human immunodeficiency virus (HIV) infection. Treatment often includes chemotherapy, and progression to non-Hodgkin lymphoma frequently occurs. MCD is characterized in part by active HHV-8 replication, and many of the symptoms of MCD may be attributable to viral gene products. We describe the effect of ganciclovir on the clinical and virologic course of MCD in a series of 3 case reports. Two patients experienced a reduction in the frequency of episodic flares of MCD and detectable HHV-8 DNA with intravenous or oral ganciclovir, whereas the third patient recovered from an acute episode of renal and respiratory failure with intravenous ganciclovir therapy. These data provide in vivo evidence for the utility of antiviral agents against HHV-8 in the management of MCD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14615380     DOI: 10.1182/blood-2003-05-1721

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  56 in total

1.  HHV-8-associated multicentric Castleman's disease in HIV-negative patient: a novel therapy for an orphan disease.

Authors:  Maria M Sbenghe; Emmanuel Besa; Amit Mahipal; Alina Dulau Florea; Paul Bray; Jaime Caro
Journal:  Oncologist       Date:  2012

2.  Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein.

Authors:  Deboeeta Chatterjee; Bala Chandran; Edward A Berger
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

3.  An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease.

Authors:  Thomas S Uldrick; Victoria Wang; Deirdre O'Mahony; Karen Aleman; Kathleen M Wyvill; Vickie Marshall; Seth M Steinberg; Stefania Pittaluga; Irina Maric; Denise Whitby; Giovanna Tosato; Richard F Little; Robert Yarchoan
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

4.  Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra).

Authors:  Hazem El-Osta; Filip Janku; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

5.  Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman's disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately.

Authors:  Xuan Lan; Zhaoming Li; Mingzhi Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-07       Impact factor: 4.553

6.  Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50/Rta lytic switch protein functions as a tetramer.

Authors:  Wei Bu; Kyla Driscoll Carroll; Diana Palmeri; David M Lukac
Journal:  J Virol       Date:  2007-03-28       Impact factor: 5.103

Review 7.  HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease.

Authors:  Ryan J Sullivan; Liron Pantanowitz; Corey Casper; Justin Stebbing; Bruce J Dezube
Journal:  Clin Infect Dis       Date:  2008-11-01       Impact factor: 9.079

Review 8.  Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma.

Authors:  Thomas S Uldrick; Denise Whitby
Journal:  Cancer Lett       Date:  2011-03-04       Impact factor: 8.679

Review 9.  Biologic Agents in the Treatment of Multicentric Castleman Disease.

Authors:  Konstantinos Kapriniotis; Savvas Lampridis; Sofoklis Mitsos; Davide Patrini; David R Lawrence; Nikolaos Panagiotopoulos
Journal:  Turk Thorac J       Date:  2018-10-01

10.  Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS).

Authors:  Mark N Polizzotto; Thomas S Uldrick; Kathleen M Wyvill; Karen Aleman; Vickie Marshall; Victoria Wang; Denise Whitby; Stefania Pittaluga; Elaine S Jaffe; Corina Millo; Giovanna Tosato; Richard F Little; Seth M Steinberg; Irini Sereti; Robert Yarchoan
Journal:  Clin Infect Dis       Date:  2015-12-12       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.